Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02775617 (Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Prevalence and determinants of scabies: A global systematic review and meta-analysis.Tropical medicine & international health : TM & IH · 2024Pooled it
- Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial.PLoS neglected tropical diseases · 2023Trial
- Community control strategies for scabies: A cluster randomised noninferiority trial.PLoS medicine · 2021Trial
- Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial.The Lancet. Infectious diseases · 2019Trial
- Disulfiram's Anti-Inflammatory and Antibacterial Effects in Fixed-Dose Combination Therapy for Scabies.Pharmaceutics · 2026Article
- Time trends in the burden of scabies from 1990 to 2021, and projections to 2050: Insights based on the Global Burden of Disease Study 2021.PLoS neglected tropical diseases · 2026Article
- Mass drug administration trials of azithromycin: an analysis to inform future research and guidelines.Infectious diseases of poverty · 2025Review
- The Incidence of Scabies in Far North Queensland, Tropical Australia: Implications for Local Clinical Practice and Public Health Strategies.Tropical medicine and infectious disease · 2025Article
- Acceptability of a nationwide scabies mass drug administration (MDA) program in Fiji: a qualitative interview-based study.The Lancet regional health. Western Pacific · 2024Article
- Prevalence and associated risk factors of scabies and impetigo: A cross-sectional study in Tutume district, Botswana.PLoS neglected tropical diseases · 2024Article
- Costs of primary healthcare presentations and hospital admissions for scabies and related skin infections in Fiji, 2018-2019.PLOS global public health · 2024Article
- Perceptions and acceptability of co-administered albendazole, ivermectin and azithromycin mass drug administration, among the health workforce and recipient communities in Ethiopia.PLoS neglected tropical diseases · 2023Article
- Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018-2019.PLoS neglected tropical diseases · 2023Article
- Article
- Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review.PLoS neglected tropical diseases · 2023Review
- Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia.EClinicalMedicine · 2023Article
- Safety of integrated preventive chemotherapy for neglected tropical diseases.PLoS neglected tropical diseases · 2022Review
- Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks.Infectious diseases of poverty · 2022Review
- Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018-2020.The Lancet regional health. Western Pacific · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundScabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.
methodsSix communities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions swabs at baseline, 3 and 12 months to detect antimicrobial resistance.
resultsAt baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 3.3% in the combined treatment arm. The proportion of impetigo lesions containing Staphylococcus aureus detected did not change (80% at baseline vs 86% at 12 months; no significant difference between arms) but the proportion containing pyogenic streptococci fell significantly (63% vs 23%, P < .01). At 3 months, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treatment arm, but no resistant strains (0/13) were detected at 12 months.
conclusionsCo-administration of azithromycin with ivermectin led to similar decreases in scabies and impetigo prevalence compared to ivermectin alone. The proportion of impetigo lesions containing pyogenic streptococci declined following MDA. There was a transient increase in the proportion of macrolide-resistant S. aureus strains following azithromycin MDA. CLINICAL TRIALS REGISTRATION: clinicaltrials.gov (NCT02775617).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.